|Videos|May 25, 2022
Recent studies investigate Phexxi for various potential indications
Author(s)Morgan Ebert
Bassem Maximos, MD, MPH, FACOG, discusses 2 recent studies investigating nonhormomal contraceptive gel Phexxi (Evofem Biosciences) for the potential treatment of UTIs and improvement in sexual satisfaction.
Advertisement
**Editors note: In an earlier version of this video, Dr. Maximos explained that 77% of women on study/using Phexxi suffered a UTI. The data actually shows that 77 women out of 1339 study subjects suffered a UTI, a notable decrease in UTIs in women using Phexxi. The video has since been edited to reflect this correction.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Updated: CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition
2
FDA grants 510(k) clearance to Roche's cobas BV/CV assay
3
Natural Cycles receives FDA clearance for AI-powered fertility algorithm
4
HIV screening, PrEP counseling get stronger ACOG recommendation
5